NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 66 resultados LastUpdate Última actualización 26/04/2017 [14:17:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

NºPublicación: EP3157553A1 26/04/2017

Solicitante:
XENCOR INC [US]

Resumen de: WO2015195498A1

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug *day/ml or more.



traducir


 

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)

NºPublicación: EP3157549A2 26/04/2017

Solicitante:
IMMATICS BIOTECHNOLOGIES GMBH [DE]

Resumen de: WO2015193359A2

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.



traducir


 

METHOD AND KIT FOR DETECTION OF DELTANOID-RESISTANT LEUKEMIA CELLS AND ANTIBODY FOR USE THEREIN

NºPublicación: EP3158340A1 26/04/2017

Solicitante:
WROCLAWSKIE CENTRUM BADA EIT + SP Z O O [PL]

Resumen de: WO2015193780A1

The present invention relates to a method and a kit and antibodies utilized therein, allowing to distinguish between leukemia cells resistant to and leukemia cells susceptible to differentiation induced by deltanoids.



traducir


 

LOBAPLATIN CRYSTAL, PREPARATION METHOD AND PHARMACEUTICAL APPLICATION

NºPublicación: EP3159349A1 26/04/2017

Solicitante:
GUIZHOU YIBAI PHARMACEUTICAL CO LTD [CN]

Resumen de: EP3159349A1

The present invention relates to new crystals A, B and F of lobaplatin as well as preparation methods therefor and pharmaceutical applications thereof. Lobaplatin crystal A has a melting point Tm.p.. of 220±5°C and is obtained by adding a lobaplatin trihydrate to a suspension crystallization solvent. Lobaplatin crystal B has a melting point Tm.p.. of 230±5°C and is obtained by performing solvent evaporation on a lobaplatin trihydrate or by adding a solvent to a lobaplatin dihydrate, and performing room temperature evaporation or solventing-out crystallization and then drying. Lobaplatin crystal F has a melting point Tm.p.. of 229±5°C and is obtained by adding methanol or ethanol to a lobaplatin dihydrate, stirring at room temperature until solids are dissolved, filtering out insolubles, slowly adding an organic solvent, crystallizing out, separating the crystal and drying the crystal. Compared with the existing lobaplatin and lobaplatin trihydrate, the lobaplatin crystals A, B and F have better stability and solubility, are more suitable for preparation of various forms of pharmaceutical preparations, are more suitable for storage and use, and can be better used for treating cancers such as breast cancer, small cell lung cancer, or chronic myeloid leukemia.



traducir


 

PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT

NºPublicación: EP3159338A2 26/04/2017

Solicitante:
KOREA RES INST CHEMICAL TECH [KR]

Resumen de: EP3159338A2

The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.



traducir


 

EZH2 INHIBITORS FOR TREATING LYMPHOMA

NºPublicación: EP3157527A1 26/04/2017

Solicitante:
EPIZYME INC [US]
EISAI R&D MAN CO LTD [JP]

Resumen de: WO2015195848A1

he present invention relates to methods of treating cancer by administering an EZH2 inhibitor or a pharmaceutical composition thereof to the subject in need thereof. The present claims define methods for treating specific subtypes of non-Hodgkin's lymphoma comprising the administration to a subject of EZH2 inhibitors. Preferred EZH2 inhibitors include tazemetostat (EPZ-6438 E7438) and other compounds. Dosage amounts and regimes are also defined.



traducir


 

COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB

NºPublicación: US2017106085A1 20/04/2017

Solicitante:
SANOFI SA [FR]
UNIV CALIFORNIA [US]

Resumen de: US2017106085A1

Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.



traducir


 

ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS

NºPublicación: US2017106003A1 20/04/2017

Solicitante:
INST FOR MYELOMA & BONE CANCER RES [US]

Resumen de: US2017106003A1

The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.



traducir


 

METHODS OF TREATING CANCER

NºPublicación: US2017105997A1 20/04/2017

Solicitante:
UNIV NORTHWESTERN [US]
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD [GB]

Resumen de: US2017105997A1

Disclosed are methods for treating cancer such as a myeloid malignancy such as multiple myeloma in a human using EZH2 inhibitors in human populations having a translocation MMSET or a decreased level of a functional UTX protein or both.



traducir


 

TREATMENTS AND DIAGNOSTICS FOR CANCERS

NºPublicación: WO2017066697A1 20/04/2017

Solicitante:
DOU QINGPING [US]
YANG HUANJIE [US]
HEATH ELISABETH I [US]

Resumen de: WO2017066697A1

Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).



traducir


 

ANTIBODY AGENTS SPECIFIC FOR HUMAN CD19 AND USES THEREOF

NºPublicación: WO2017066136A2 20/04/2017

Solicitante:
EUREKA THERAPEUTICS INC [US]

Resumen de: WO2017066136A2

Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.



traducir


 

PYRROLOBENZODIAZEPINE COMPOUNDS FOR TREATING LYMPHOMA

NºPublicación: US2017107235A1 20/04/2017

Solicitante:
ADC PRODUCTS (UK) LTD [GB]

Resumen de: WO2015181559A1

A method of treating a patient suffering from lymphoma comprising administering to said patient a therapeutically active amount of a compound formula I, or pharmaceutically acceptable salt or solvate thereof, wherein: the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R2 and R3 are independently selected from -H, =O, =CH2, -CN, -R, OR, halo, =CH-R, O-SO2-R, CO2R and COR; R6, R7 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted C1-12alkyl, C3-20heterocyclyl and C5-20aryl groups; R" is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NH, and/or aromatic rings, e.g. benzene or pyridine, and each X is independently selected from O, S, or NH; R2', R3', R6', R7' and R9' are all independently selected from the same lists as previously defined for R2, R3, R6, R7 and R9 respectively.



traducir


 

PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1

NºPublicación: US2017107252A1 20/04/2017

Solicitante:
AILERON THERAPEUTICS INC [US]

Resumen de: US2017107252A1

The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.



traducir


 

CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS AS PIN1 MODULATORS

NºPublicación: WO2017063754A1 20/04/2017

Solicitante:
POLYPHOR AG [CH]

Resumen de: WO2017063754A1

Conformationally constrained macrocyclic compounds of formula (I), including substituents E, G, and Q, as defined in the description and the claims, and salts thereof, have the property to modulate the activity of the peptidyl-prolyl cis/trans isomerases Pin1. Thus, these compounds and pharmaceutical compositions containing said compounds may be useful in the treatment and/or prevention of diseases or conditions in the area of proliferative disorders and diseases, such as e.g. cancer, inflammatory diseases, transplant rejection, viral infections, osteolytic bone diseases, cardiac diseases, cardiovascular diseases, respiratory diseases, acute neurological diseases, neurodegenerative diseases, immune disorders, and lymphoproliferative theileriosis.



traducir


 

CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS

NºPublicación: WO2017063755A1 20/04/2017

Solicitante:
POLYPHOR AG [CH]

Resumen de: WO2017063755A1

Formula (I); Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to compounds that have the property to modulate the activity of the peptidyl-prolyl cis/trans isomerase Pin1. In addition, they show antiproliferative activity on various cancer cell lines. Thus, these compounds and pharmaceutical compositions containing said compounds may be useful in the treatment and/or prevention of diseases or conditions in the area of proliferative disorders and diseases, such as e.g. cancer, inflammatory diseases, transplant rejection, viral infections, osteolytic bone diseases, cardiac diseases, cardiovascular diseases, respiratory diseases, acute neurological diseases, neurodegenerative diseases, immune disorders, and lymphoproliferative theileriosis.



traducir


 

APPLICATION OF TRICIRIBINE AND/OR METABOLITE THEREOF IN TREATING ACUTE LEUKEMIA CARRYING FLT3 MUTANT GENES

NºPublicación: WO2017063209A1 20/04/2017

Solicitante:
CAS (HEFEI) INST OF TECH INNOVATION [CN]

Resumen de: WO2017063209A1

Application of triciribine and/or a metabolite thereof in preparing a drug for treating an acute myelocytic leukemia patient carrying FLT3 mutant genes. A patient suffering from leukemia may have or may not have drug resistance associated with high expression of an FL ligand. A method having a non-treatment goal and inhibiting acute myelocytic leukemia cells carrying FLT3 mutant genes comprises: enabling the cells to be in contact with triciribine and/or a metabolite thereof.



traducir


 

CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS

NºPublicación: WO2017063757A1 20/04/2017

Solicitante:
POLYPHOR AG [CH]

Resumen de: WO2017063757A1

Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to compounds that have the property to modulate the activity of the peptidyl-prolyl cis/trans isomerase Pin1. In addition, they show antiproliferative activity on various cancer cell lines. Thus, these compounds and pharmaceutical compositions containing said compounds may be useful in the treatment and/or prevention of diseases or conditions in the area of proliferative disorders and diseases, such as e.g. cancer, inflammatory diseases, transplant rejection, viral infections, osteolytic bone diseases, cardiac diseases, cardiovascular diseases, respiratory diseases, acute neurological diseases, neurodegenerative diseases, immune disorders, and lymphoproliferative theileriosis.



traducir


 

CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS AS PIN1 MODULATORS

NºPublicación: WO2017063756A1 20/04/2017

Solicitante:
POLYPHOR AG [CH]

Resumen de: WO2017063756A1

Conformationally constrained macrocyclic compounds of formula (I), including substituents E, G, and Q, as defined in the description and the claims, and salts thereof, have the property to modulate the activity of the peptidyl-prolyl cis/trans isomerases Pin1. Thus, these compounds and pharmaceutical compositions containing said compounds may be useful in the treatment and/or prevention of diseases or conditions in the area of proliferative disorders and diseases, such as e.g. cancer, inflammatory diseases, transplant rejection, viral infections, osteolytic bone diseases, cardiac diseases, cardiovascular diseases, respiratory diseases, acute neurological diseases, neurodegenerative diseases, immune disorders, and lymphoproliferative theileriosis.



traducir


 

IL-17 ANTIBODY FORMULATION

NºPublicación: EP3156073A1 19/04/2017

Solicitante:
LILLY CO ELI [US]

Resumen de: EP3156073A1

The present invention provides pharmaceutical formulations for anti-IL-17 antibodies. These anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.



traducir


 

TREATING MYELOMAS

NºPublicación: EP3154595A1 19/04/2017

Solicitante:
MAYO FOUNDATION [US]

Resumen de: WO2015195476A1

This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.



traducir


 

TREATING LYMPHOMAS

NºPublicación: EP3154586A1 19/04/2017

Solicitante:
MAYO FOUNDATION [US]

Resumen de: WO2015191969A1

This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.



traducir


 

MEANS AND METHODS FOR PREDICTING AN EXTRAMEDULLARY RELAPSE IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

NºPublicación: EP3155423A1 19/04/2017

Solicitante:
ERASMUS UNIV MEDICAL CENTER ROTTERDAM [NL]

Resumen de: WO2015190931A1

The invention relates to the field of cancer diagnosis and therapy design, in particular diagnosis of extramedullary (EM) involvement in a subject afflicted with acute lymphoblastic leukemia. Provided is a method comprising determining in ALL cells the relative level and/or absolute amount of Stearoyl-Co A desaturase (SCD; EC 1.14.19.1) protein; and correlating the level and/or absolute amount of the SCD protein with the risk of developing an EM relapse, wherein an increased level and/or absolute amount of SCD relative to a control sample is indicative of having an increased risk of developing an extramedullary relapse. Also provided are reagent compositions and a diagnostic kit.



traducir


 

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

NºPublicación: EP3154536A1 19/04/2017

Solicitante:
INST NAT DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE (INSERM) [FR]
FOND IMAGINE [FR]
ASSIST PUBLIQUE-H\u00D4PITAUX DE PARIS (APHP) [FR]
UNIVERSIT\u00C9 PARIS DESCARTES [FR]
CENTRE NAT DE LA RECH SCIENT (C N R S ) [FR]

Resumen de: WO2015189186A1

The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndromeby preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.



traducir


 

ANTIBODIES AGAINST CSF-1R

NºPublicación: EP3156419A1 19/04/2017

Solicitante:
IMCLONE LLC [US]

Resumen de: EP3156419A1

The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention are multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.



traducir


 

NEW BIOMARKER FOR OUTCOME IN AML PATIENTS

Nº publicación: US2017102389A1 13/04/2017

Solicitante:
INSERM (INSTITUT NAT DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
INST JEAN PAOLI & IRENE CALMETTES [FR]
CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]
UNIVERSIT\u00C9 D'AIX MARSEILLE [FR]

Resumen de: US2017102389A1

The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) comprising i) determining in a sample obtained from the patient the expression level of NKp46 ii) comparing the expression level determined at step i) with its predetermined reference value and iii) providing a good prognosis when the expression level determined at step i) is higher than its predetermined reference value, or providing a bad prognosis when the expression level determined at step i) is lower than its predetermined reference value.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver